Author

Marianniz Díaz-Hernández

Observed names: Díaz-Hernández, Marianniz, Marianniz Diaz, Marianniz Díaz

Institution: Center of Molecular Immunology (Cuba)

Observed institution: Center of Molecular Immunology (Cuba)

ORCID: 0000-0001-6838-2568

Observed ORCID: 0000-0001-6838-2568

OpenAlex ID: A5002829716

A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial

2021 · Arturo Chang-Monteagudo, Rolando Ochoa-Azze, et al. · The Lancet Regional Health - Americas · 51

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

2022 · María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, et al. · Vaccine · 38

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · International Journal of Infectious Diseases · 33

Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults

2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · Med · 31

A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles

2021 · Darielys Santana-Mederos, Rocmira Perez-Nicado, et al. · RSC Chemical Biology · 30

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

2022 · Rolando Ochoa-Azze, Arturo Chang-Monteagudo, et al. · The Lancet Respiratory Medicine · 29

A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies

2022 · Franciscary Pi-Estopiñan, María Teresa Pérez, et al. · Vaccine · 10

Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · medRxiv · 5

PEGylation Strategy for Improving the Pharmacokinetic and Antitumoral Activity of the IL-2 No-alpha Mutein

2023 · Marianniz Díaz-Hernández, Janoi Chang-Calderón, et al. · Current Pharmaceutical Design · 2

Studying the Humoral Response against SARS‐CoV‐2 in Cuban COVID‐19 Recovered Patients

2024 · Ivette Orosa Vázquez, Marianniz Díaz, et al. · Journal of Immunology Research · 1

Primer brote de COVID-19 en Cuba. Factores de riesgo de morbimortalidad y respuesta específica de anticuerpos en convalecientes

2024 · Zuñiga Rosales, Yaima, Marcheco-Teruel, Beatriz, et al. · Anales de la Academia de Ciencias de Cuba

Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial

2022 · Maria Eugenia-Toledo-Romani, Mayra García Carmenate, et al. · SSRN Electronic Journal

Detection by immunoperoxidase of a B cell antigen in poststreptococcal and other vasculitides

1992 · Jacobo Futran, Usha Pulakhandam, et al.

Works count: 13

Citation count: 230

H-index: 7

I10-index: 7